Should I Buy REPL? REPL 2026 Analysis

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.040

1 Day change

10.74%

52 Week Range

14.800

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Replimune Group Inc (REPL) does not present a strong buy opportunity for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals or recent news to drive immediate upside. While there is potential for future growth with the upcoming PDUFA date in April, the current pre-market price and technical indicators suggest a wait-and-see approach is more prudent.

Technical Analysis

The MACD histogram is positive at 0.15, indicating slight bullish momentum. RSI is neutral at 68.376, and moving averages are converging, showing no clear trend. The stock is trading near its first resistance level (R1: 7.929), suggesting limited immediate upside.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data shows a strong bullish sentiment with a low put-call ratio, but the implied volatility is very high (223.12%), indicating significant risk.

Technical Summary

Sell

Buy

Positive Catalysts

The upcoming PDUFA date for RP1 in April could act as a future catalyst. Piper Sandler raised the price target to $14 and maintains an Overweight rating, showing analyst optimism.

Neutral/Negative Catalysts

The company has no recent news or significant insider/hedge fund activity. Financial performance remains weak with negative net income (-$70.93M) and declining EPS (-2.53% YoY). There is no recent congress trading data, and the stock has a 60% chance of only minor short-term gains.

Financial Performance

In Q3 2026, revenue remained at $0, with no growth. Net income improved slightly YoY (-$70.93M, up 6.92%), but EPS dropped to -0.77 (-2.53% YoY). Gross margin remains at 0, indicating no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Piper Sandler raised the price target to $14 from $13 and maintains an Overweight rating. Analysts are cautiously optimistic about the RP1 approval but acknowledge risks due to FDA concerns.

7 Analyst Rating

Wall Street analysts forecast REPL stock price to rise

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 7.260

Low

Averages

11.43

High

Current: 7.260

Low

Averages

11.43

High

Piper Sandler

Overweight

maintain

$13 -> $14

AI Analysis

2026-02-05

Reason

Piper Sandler

Price Target

$13 -> $14

AI Analysis

2026-02-05

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Replimune to $14 from $13 and keeps an Overweight rating on the shares following Q3 reporting and ahead of RP1's April 10 PDUFA date. Replimune has felt the full brunt of the impact of FDA turmoil and seemingly capricious decision-making in recent months, Piper notes. The firm understands that additional analyses addressing FDA's concern around the contribution of components in the single-arm IGNYTE trial played a key role in this apparent about-face, and finds these recently disclosed analyses compelling. While Piper acknowledges that RP1's approval decision still carries risk, it's the firm's sense that FDA wouldn't have accepted the resubmission with the intent of rejecting it a second time.

BMO Capital

Evan Seigerman

Underperform

Market Perform

upgrade

$2 -> $11

2025-11-03

Reason

BMO Capital

Evan Seigerman

Price Target

$2 -> $11

2025-11-03

upgrade

Underperform

Market Perform

Reason

BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REPL

Unlock Now

REPL Should I Buy

REPL Should I Buy

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch